The new agency will focus on the development and delivery of payer and reimbursement strategies for the managed markets sector in the US.
Claire Gillis CEO VMLY&Rx
“This offer continues the momentum from the launch of our global pharmaceutical network VMLY&Rx last year. Our VMLY&Rx Payer team will focus on connecting the complex and ever-evolving US payer market at a critical time for patients as the sector moves beyond the pandemic. Creating connected health experiences that help promote access to innovative therapies has never been more important.”
HeeSun Yu President of VMLY&Rx Payer adds:
“Payers and population health decision makers (PHDM) are the gatekeepers to healthcare in the US. They play a huge role in determining whether patients can access innovative medicines. Payer engagement is therefore key to the success to our healthcare system. Our clients need partners who are fluent in their language. They need us to intrinsically understand the connections and complexities between healthcare’s diverse cultures and harness its unique challenges and opportunities. This is the time to be in heath and there’s a tangible energy within VMLY&Rx - I’m excited to be part of it.”
HeeSun Yu is a senior level healthcare marketing executive with over 22 years of ad agency experience. Starting her career in medical research at Rockefeller University with a focus on neurobehavioral science, she later transitioned into the agency world to focus on HCP, patient marketing, data analytics, behavioral science and health economics. She has a wealth of experience across many therapeutic categories including asthma, allergy, COPD, diabetes, immunology, dermatology, rare diseases, neuroscience and oncology.
The VMLY&Rx Payer team will provide strategic support to US clients across the product lifecycle including the delivery of patient-centred, value-focused access and reimbursement strategies. VMLY&R Payer will form part of the wider global health offer for VMLY&Rx.